Delamanid in the treatment of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S33-S37

  Gupta, R ^a   Wells, C D ^b   Hittel, N ^c   Hafkin, J ^a   Geiter, L J ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b SANOFI   (France)

^c Otsuka Novel Products GmbH   (Germany)

Author keywords

Anti tuberculosis treatment; DLM; DLM for pulmonary MDR TB; MDR TB

Indexed keywords

CLOFAZIMINE; DELAMANID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; AUC (0-24 H); DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAXIMUM CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL PROTOCOL;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NITROIMIDAZOLES; OXAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85018405419     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0125     Document Type: Article

References (37)

1. Otsuka Pharmaceutical. 1964-2014 chronicle: our 50-year history. Tokyo, Japan: Otsuka, 2015.
2. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
3. Ryan N J, Lo J H. Delamanid: first global approval. Drugs 2014; 74: 1041-1045.
4. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. WHO/HTM/TB2014.23. Geneva, Switzerland: WHO, 2014.
5. th WHO Model List of Essential Medicines. Geneva, Switzerland: WHO, 2015. http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf Accessed August 2016.
6. Diel R, Hittel N, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany. Respir Med 2015; 109: 632-641.
7. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med 2006; 3: e466.
8. Shimokawa Y, Sasahara K, Yoda N, Mizuno K, Umehara K. Delamanid does not inhibit or induce cytochrome P450 enzymes in vitro. Biol Pharm Bull 2014; 37: 1727-1735.
9. Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother 2016; 60: 5976-5985.
10. European Medicines Agency. Deltyba Assessment Report. EMA/55567/2014. London, UK: EMA, 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/002552/WC500166234.pdf Accessed August 2016.
11. Saliu O Y, Crismale C, Schwander S K, Wallis R S. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother 2007; 60: 994-998.
12. Stinson K, Kurepina N, Venter A, et al. Minimum inhibitory concentration of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 2016; 60: 3316-3322.
13. European Medicines Agency. Deltyba summary of product characteristics. London, UK: EMA, 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Product-Information/human/002552/WC500166232.pdf Accessed August 2016.
14. Blair H A, Scott L J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015; 75: 91-100.
15. Diacon A H, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
16. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
17. Wells C D, Gupta R, Hittel N, Geiter L J. Long-term mortality assessment of multidrug resistant tuberculosis patients treated with delamanid. Eur Respir J 2015; 45: 1498-1501.
18. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
19. Gammino V M, Taylor A B, Rich M L, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Administration and Research. Guidance for industry pulmonary tuberculosis: developing drugs for treatment. 10577dft.doc. Washington DC, USA: FDA, 2013.
21. European Medicines Agency, Committee for Medical Products for Human Use. Addendum to the note for guidance on evaluation of medicinal products indicated for the treatment of bacterial infections to specifically address clinical development of new agents to treat disease due to Mycobacterium tuberculosis. Ref. EMEA/CHMP/EWP/14377/2008. London, UK: EMA, 2008.
22. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
23. Gupta R, Geiter L J, Hafkin J H, Wells C D. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015; 19: 1261-1262.
24. Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori G B. Delamanid (OPC-67683) for the treatment of multidrug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 305-315.
25. Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf 2015; 38: 253-269.
26. Gupta R, Geiter L J, Wells C D. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015; 373: 291-292.
27. Hafkin J, Frias M, Hesseling A, et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6-17 years. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. [Poster A-960]. San Diego, CA, USA: ICAAC, 17-25 September 2015.
28. th Union World Conference on Lung Health Cape Town, South Africa, 2-6 December 2015. Int J Tuberc Lung Dis 2015: 19 (12 Suppl 2): S91. [EP-115-04].
29. European Medicines Agency. European Medicines Agency decision P/0281/2014. EMA/587559/2014. London, UK: EMA, 2014. http://www.ema.europa.eu/docs/en-GB/document-library/PIP-decision/WC500178675.pdf Accessed August 2016.
30. Tupasi T, Gupta R, Danilovits M, et al. Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis. Bull World Health Organ 2016; 94: 147-152.
31. Treatment Action Group. Tuberculosis Research and Development: 2014 Report on Tuberculosis Research Funding Trends, 2005-2013. New York, NY, USA: TAG, 2014.
32. Brigden G, Nyang'wa B T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014; 92: 68-74.
33. Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177-186.
34. World Health Organization. Companion handbook for the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014.
35. World Economic Forum. Declaration by the pharmaceutical, biotechnology and diagnostics industries on combating antimicrobial resistance. Davos, Switzerland: WEF, 2016. http://amr-review.org/sites/default/files/Industry-Declaration-of-support-for-combating-AMR-UPDATED-SIGNATORIES-APR-2016.pdf Accessed August 2016.
36. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl 2): S241-S249.
37. rd. Timing is everything for compassionate use of delamanid. Nat Med 2015; 21: 211.